Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human follistatin
- Development stage
- Preclinical
- Lead developer
- Paranta Biosciences
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Systemic
01
Overview
Recombinant human follistatin is a manufactured glycoprotein that functions as a natural antagonist to various members of the transforming growth factor-beta (TGF-β) superfamily, including activin, myostatin, bone morphogenetic proteins (BMPs), and Growth Differentiation Factor 11 (GDF-11). It exerts its effects by binding to these ligands, thereby preventing their interaction with signaling receptors and modulating downstream cellular processes. This specific recombinant human follistatin is being developed by Paranta Biosciences Ltd, with manufacturing support from DSM, and is intended for the treatment of respiratory diseases.
- Other names
- FSactivin-binding proteinFSH-suppressing proteinFSP
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)GDF8 (Myostatin)ACT (Actin beta-like protein 2)GDF11 (Growth differentiation factor 11)
Beyond the preview
Go deeper on recombinant human follistatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human follistatin.